BDBM224241 3-{6-[3-chloro-5-(2- methoxyethoxy)phen- yl]-8-[(trans)- hexahydrocyclopenta [b][1,4]oxazin- 4(4ah)-yl]-7-[(trans- 4- methylcyclohexyl) methyl]-7h-purin-2-yl}- 1,2,4-oxadiazol- 5(4h)-one (racemate)::US9540377, 16.160

SMILES COCCOc1cc(Cl)cc(-c2nc(-c3noc(=O)[nH]3)nc3nc(N4CCOC5CCCC54)n(C[C@H]4CC[C@H](C)CC4)c23)c1

InChI Key InChIKey=FKFCTGIGSXYQKX-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 224241   

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandChemical structure of BindingDB Monomer ID 224241BDBM224241(US9540377, 16.160 | 3-{6-[3-chloro-5-(2- methoxyet...)
Affinity DataIC50: 21nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2018
Entry Details
US Patent